Overview

* Pediatrix Q2 revenue beats analyst expectations, driven by neonatology volumes

* Adjusted EBITDA for Q2 exceeds estimates

* Company raises full-year 2025 adjusted EBITDA outlook

Outlook

* Pediatrix raises full-year 2025 Adjusted EBITDA outlook to $245 mln-$255 mln

* Company remains cautious amid turbulent healthcare environment

* Company believes financial flexibility provides safety and opportunity

Result Drivers

* NEONATOLOGY VOLUMES - Strong neonatology patient volumes contributed to increased same-unit revenue

* PAYOR MIX - Stable payor mix and improved collection activity supported revenue

* PRACTICE DISPOSITIONS - Decrease in net revenue due to practice dispositions, offset by same-unit growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $468.84 $464.30

Revenue mln mln (8

Analysts

)

Q2 Net $39.26

Income mln

Q2 Beat $73.25 $59.70

Adjusted mln mln (7

EBITDA Analysts

)

Q2 $59.87

Income mln

from

operatio

ns

Q2 $408.98

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Pediatrix Medical Group Inc ( MD ) is $16.00, about 23.1% above its August 4 closing price of $12.30

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)